LUND, Sweden, May 21, 2024 /PRNewswire/ . Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Kidney Donations: A Halachic Analysis of a Shocking Ruling – by Rabbi Yair Hoffman theyeshivaworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theyeshivaworld.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results.